MEDP Share Price Performance
US$436.30
56.30 (14.82%)
14.5% undervalued intrinsic discount
US$510.00
Fair Value
Price US$436.30
AnalystHighTarget US$510.00
AnalystConsensusTarget US$401.27
AnalystLowTarget US$297.34
Fair ValueUS$510.00
Share PriceUS$436.30
14.5% undervalued intrinsic discount
MEDP Community Narratives
AN
Fair Value US$510.00 14.5% undervalued intrinsic discount
Biopharma Outsourcing And Decentralized Trials Will Redefine Markets
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value US$401.27 8.7% overvalued intrinsic discount
Tech-enabled Clinical Trials Will Balance Potential Risk And Reward
0users have liked this narrative
0users have commented on this narrative
25users have followed this narrative
AN
Fair Value US$297.34 46.7% overvalued intrinsic discount
Accelerating Costs And Funding Risk Will Undermine Biotech Stability
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
MEDP Community Fair Values
- US$401.27FV8.7% overvalued intrinsic discount11.66%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative25users have followed this narrative6 days ago author updated this narrative
- US$510.00FV14.5% undervalued intrinsic discount15.46%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative1users have followed this narrative9 days ago author updated this narrative
- US$297.34FV46.7% overvalued intrinsic discount3.39%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative0users have followed this narrative9 days ago author updated this narrative
Recent MEDP News & Updates
No updates
Medpace Holdings, Inc. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 14.89
- Gross Margin
- 68.51%
- Net Profit Margin
- 18.74%
- Debt/Equity Ratio
- 0%
Medpace Holdings, Inc. Competitors
About MEDP
- Founded
- 1992
- Employees
- 6000
- CEO
- WebsiteView website
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
U.S. Market Performance
- 7 Days: -1.2%
- 3 Months: 12.3%
- 1 Year: 21.3%
- Year to Date: 7.0%
Over the past 7 days, the market has dropped 1.2% with the Consumer Discretionary sector contributing the most to the decline. In contrast to the last week, the market is actually up 21% over the past year. Earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading